Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162067594> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W3162067594 endingPage "89" @default.
- W3162067594 startingPage "88" @default.
- W3162067594 abstract "Aims: Presented herein are the post Week 48 through Week 96 resistance analyses for Phase 3 studies evaluating tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF).Methods: Patients were randomized 2:1. HBV pol/RT popula tion or deep sequencing was conducted for patients with vire mia at Week 96 or at early discontinuation post Week 48. Deep sequencing was conducted for patients with HBV DNA >159 IU/mL and sequence changes at the consensus sequence level are reported. Phenotypic analysis was performed for Virologic breakthrough (VB) patients who were adherent to study drug, patients with conserved site substitutions, or for polymorphic substitutions emergent in >1 patient.Results: TAF and TDF were treated in 866 and 432 patients, respectively. A similar percentage of patients in the arms quali fied for sequence analysis. In the TAF arm, 87 (10.5%) patients qualified: 31 had no sequence change from baseline, 15 were unable to sequence (UTS), 32 had polymorphic site substitu tions, and 9 had conserved site substitutions. In the TDF arm, 45 (10.9%) patients qualified: 26 had no sequence change, 6 were UTS, 11 had polymorphic site substitutions, and 2 had conserved site substitutions. Each detected conserved site sub stitution other than rtA181T was observed in one patient. The rtA181T substitution in 2 patients, 1 from each arm, was not associated with increasing plasma HBV DNA levels. At Week 96, a small percentage of patients experienced VB, and VB was often associated with nonadherence. 27 patients qualified for phenotypic analysis and no patient isolates tested showed a reduction in susceptibility to TAF or tenofovir, respectively.Conclusions: The proportion of patients analyzed and the HBV sequence changes observed were similar between patients in the TAF and TDF arms. Most substitutions occurred at polymor phic positions and no substitutions associated with resistance to TAF were detected through 96 weeks of treatment." @default.
- W3162067594 created "2021-05-24" @default.
- W3162067594 creator A5008851778 @default.
- W3162067594 creator A5012779251 @default.
- W3162067594 creator A5013246678 @default.
- W3162067594 creator A5014107752 @default.
- W3162067594 creator A5025938903 @default.
- W3162067594 creator A5026290406 @default.
- W3162067594 creator A5035543985 @default.
- W3162067594 creator A5041011561 @default.
- W3162067594 creator A5050079986 @default.
- W3162067594 creator A5066924600 @default.
- W3162067594 creator A5069582580 @default.
- W3162067594 creator A5071416215 @default.
- W3162067594 creator A5081575577 @default.
- W3162067594 creator A5088424983 @default.
- W3162067594 date "2018-01-01" @default.
- W3162067594 modified "2023-09-25" @default.
- W3162067594 title "PO-021 : No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B" @default.
- W3162067594 hasPublicationYear "2018" @default.
- W3162067594 type Work @default.
- W3162067594 sameAs 3162067594 @default.
- W3162067594 citedByCount "0" @default.
- W3162067594 crossrefType "journal-article" @default.
- W3162067594 hasAuthorship W3162067594A5008851778 @default.
- W3162067594 hasAuthorship W3162067594A5012779251 @default.
- W3162067594 hasAuthorship W3162067594A5013246678 @default.
- W3162067594 hasAuthorship W3162067594A5014107752 @default.
- W3162067594 hasAuthorship W3162067594A5025938903 @default.
- W3162067594 hasAuthorship W3162067594A5026290406 @default.
- W3162067594 hasAuthorship W3162067594A5035543985 @default.
- W3162067594 hasAuthorship W3162067594A5041011561 @default.
- W3162067594 hasAuthorship W3162067594A5050079986 @default.
- W3162067594 hasAuthorship W3162067594A5066924600 @default.
- W3162067594 hasAuthorship W3162067594A5069582580 @default.
- W3162067594 hasAuthorship W3162067594A5071416215 @default.
- W3162067594 hasAuthorship W3162067594A5081575577 @default.
- W3162067594 hasAuthorship W3162067594A5088424983 @default.
- W3162067594 hasConcept C126322002 @default.
- W3162067594 hasConcept C142462285 @default.
- W3162067594 hasConcept C159047783 @default.
- W3162067594 hasConcept C2522874641 @default.
- W3162067594 hasConcept C2777382497 @default.
- W3162067594 hasConcept C2778715236 @default.
- W3162067594 hasConcept C2780593183 @default.
- W3162067594 hasConcept C2911190787 @default.
- W3162067594 hasConcept C2993143319 @default.
- W3162067594 hasConcept C54355233 @default.
- W3162067594 hasConcept C552990157 @default.
- W3162067594 hasConcept C61053724 @default.
- W3162067594 hasConcept C71924100 @default.
- W3162067594 hasConcept C86803240 @default.
- W3162067594 hasConcept C90924648 @default.
- W3162067594 hasConceptScore W3162067594C126322002 @default.
- W3162067594 hasConceptScore W3162067594C142462285 @default.
- W3162067594 hasConceptScore W3162067594C159047783 @default.
- W3162067594 hasConceptScore W3162067594C2522874641 @default.
- W3162067594 hasConceptScore W3162067594C2777382497 @default.
- W3162067594 hasConceptScore W3162067594C2778715236 @default.
- W3162067594 hasConceptScore W3162067594C2780593183 @default.
- W3162067594 hasConceptScore W3162067594C2911190787 @default.
- W3162067594 hasConceptScore W3162067594C2993143319 @default.
- W3162067594 hasConceptScore W3162067594C54355233 @default.
- W3162067594 hasConceptScore W3162067594C552990157 @default.
- W3162067594 hasConceptScore W3162067594C61053724 @default.
- W3162067594 hasConceptScore W3162067594C71924100 @default.
- W3162067594 hasConceptScore W3162067594C86803240 @default.
- W3162067594 hasConceptScore W3162067594C90924648 @default.
- W3162067594 hasIssue "1" @default.
- W3162067594 hasLocation W31620675941 @default.
- W3162067594 hasOpenAccess W3162067594 @default.
- W3162067594 hasPrimaryLocation W31620675941 @default.
- W3162067594 hasRelatedWork W1554907252 @default.
- W3162067594 hasRelatedWork W1911488210 @default.
- W3162067594 hasRelatedWork W2021660989 @default.
- W3162067594 hasRelatedWork W2023094053 @default.
- W3162067594 hasRelatedWork W2110109022 @default.
- W3162067594 hasRelatedWork W2125211506 @default.
- W3162067594 hasRelatedWork W2145194297 @default.
- W3162067594 hasRelatedWork W2145349124 @default.
- W3162067594 hasRelatedWork W2166098777 @default.
- W3162067594 hasRelatedWork W2409307896 @default.
- W3162067594 hasRelatedWork W2409844399 @default.
- W3162067594 hasRelatedWork W2883340373 @default.
- W3162067594 hasRelatedWork W2916210155 @default.
- W3162067594 hasRelatedWork W2995517530 @default.
- W3162067594 hasRelatedWork W3030034665 @default.
- W3162067594 hasRelatedWork W3042726352 @default.
- W3162067594 hasRelatedWork W3158152815 @default.
- W3162067594 hasRelatedWork W3160921878 @default.
- W3162067594 hasRelatedWork W3162754925 @default.
- W3162067594 hasRelatedWork W2739901145 @default.
- W3162067594 hasVolume "2018" @default.
- W3162067594 isParatext "false" @default.
- W3162067594 isRetracted "false" @default.
- W3162067594 magId "3162067594" @default.
- W3162067594 workType "article" @default.